Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $230.91 million. The enterprise value is $137.18 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 363.18 million shares outstanding. The number of shares has increased by 48.46% in one year.
| Current Share Class | 363.18M |
| Shares Outstanding | 363.18M |
| Shares Change (YoY) | +48.46% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 27.51% |
| Float | 183.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.95 |
| Forward PS | 6.67 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 2.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.86.
| Current Ratio | 2.22 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.25 |
Financial Efficiency
Return on equity (ROE) is -86.09% and return on invested capital (ROIC) is -33.06%.
| Return on Equity (ROE) | -86.09% |
| Return on Assets (ROA) | -28.88% |
| Return on Invested Capital (ROIC) | -33.06% |
| Return on Capital Employed (ROCE) | -88.33% |
| Revenue Per Employee | $303,039 |
| Profits Per Employee | -$1.72M |
| Employee Count | 103 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 234.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.53% in the last 52 weeks. The beta is 1.08, so LXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -62.53% |
| 50-Day Moving Average | 0.58 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 51.76 |
| Average Volume (20 Days) | 3,719,483 |
Short Selling Information
The latest short interest is 43.03 million, so 11.85% of the outstanding shares have been sold short.
| Short Interest | 43.03M |
| Short Previous Month | 37.27M |
| Short % of Shares Out | 11.85% |
| Short % of Float | 23.42% |
| Short Ratio (days to cover) | 7.75 |
Income Statement
In the last 12 months, LXRX had revenue of $31.21 million and -$177.30 million in losses. Loss per share was -$0.51.
| Revenue | 31.21M |
| Gross Profit | -52.76M |
| Operating Income | -165.16M |
| Pretax Income | n/a |
| Net Income | -177.30M |
| EBITDA | -164.60M |
| EBIT | -165.16M |
| Loss Per Share | -$0.51 |
Full Income StatementBalance Sheet
The company has $194.84 million in cash and $106.26 million in debt, giving a net cash position of $88.58 million or $0.24 per share.
| Cash & Cash Equivalents | 194.84M |
| Total Debt | 106.26M |
| Net Cash | 88.58M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 123.03M |
| Book Value Per Share | 0.34 |
| Working Capital | 135.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$167.43 million and capital expenditures -$1.03 million, giving a free cash flow of -$168.46 million.
| Operating Cash Flow | -167.43M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -168.46M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
| Gross Margin | -169.04% |
| Operating Margin | -529.15% |
| Pretax Margin | -568.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.46% |
| Shareholder Yield | -48.46% |
| Earnings Yield | -78.54% |
| FCF Yield | -74.62% |
Analyst Forecast
The average price target for LXRX is $3.67, which is 477.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.67 |
| Price Target Difference | 477.23% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 43.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 0.1428571:1.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1428571:1 |
Scores
LXRX has an Altman Z-Score of -8.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.94 |
| Piotroski F-Score | 4 |